The use of an LH
阅读量：
36
摘要：
Fifty-three premenopausal patients presenting with advanced breast cancer have been treated with a potent new luteinising hormone-releasing hormone agonist Zoladex (ICI 118630) in a phase I clinical trial. On progression of disease 26 patients have undergone therapeutic oophorectomy. We present the clinical and endocrinological responses to treatment in 45 assessable patients. The response rate to Zoladex in this series was 31% and the ER status of the primary tumour was predictive of a response to the luteinising hormone-releasing hormone.
展开
关键词：
Humans Breast Neoplasms Estradiol Progesterone Follicle Stimulating Hormone Luteinizing Hormone Buserelin Goserelin Receptors, Estrogen Delayed-Action Preparations
DOI：
10.1038/bjc.1986.106
被引量：
年份：
1986
Nature
(全网免费下载)
Semantic Scholar
(全网免费下载)
Europe PMC
(全网免费下载)
NCBI
(全网免费下载)
ResearchGate
查看更多
ProQuest
ResearchGate
(全网免费下载)
EBSCO
www.socolar.com
biomedsearch.com
(全网免费下载)
Nature
(全网免费下载)
Semantic Scholar
(全网免费下载)
NCBI
(全网免费下载)
Europe PMC
(全网免费下载)
ResearchGate
(全网免费下载)
biomedsearch.com
(全网免费下载)
通过文献互助平台发起求助，成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
来源期刊
引用走势
站内活动
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用！
